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Abstract 
 
Leptomeningeal dissemination of tumor cells, also referred to as neoplastic meningitis, is 
most frequently seen in patients with late-stage cancer and mostly associated with a poor 
prognosis. Basically, neoplastic meningitis may affect all patients with malignant tumor but is 
most common in patients affected by lung cancer, breast carcinoma, melanoma or 
hematologic neoplasms such as lymphoma and leukemia. Controlled clinical trials are largely 
lacking which results in various non-standardized treatment regimens. The presence of solid 
tumor manifestations in the CNS as well as the extracranial tumor load defines the most 
appropriate treatment approach. Radiation therapy, systemic chemotherapy and intrathecal 
treatment must be considered. For each patient, the individual situation needs to be carefully 
evaluated to determine the potential benefit as well as putative side effects associated with 
any therapy. A moderate survival benefit and particularly relief from pain and neurological 
deficits are the main treatment goals. Here, we summarize the management of patients with 
neoplastic meningitis and review the available treatment options.  
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Introduction 
 
Neoplastic meningitis represents a spread of tumor cells into the subarachnoid space. 
Cancer cells may reach the leptomeninges through hematogenous spread, direct infiltration 
from tumor manifestations in the brain parenchyma or spread along the perineurium from 
cranial or spinal nerves. Based on the histological characterization of the underlying tumor, it 
is also referred to as leptomeningeal carcinomatosis, gliomatosis or lymphomatosis, 
respectively. Basically, all malignant tumors may cause neoplastic meningitis. However, 
similar to solid metastases to the CNS, there are several tumor entities which are much more 
frequently associated with leptomeningeal spread than others. Among the most common 
primary tumors associated with leptomeningeal dissemination are lung and breast cancer, 
melanoma as well as lymphoma and leukemia 1. Leptomeningeal spread is also observed in 
patients diagnosed with primary brain tumors such as medulloblastoma, germinoma or PNET 
whereas gliomas metastasize to the subarachnoid space less frequently. Neoplastic 
meningitis is found in approximately 5-10% of all patients with malignant tumors and is a 
condition frequently diagnosed in late stage cancer 2. Leptomeningeal tumor dissemination is 
associated with poor prognosis in patients with solid tumor and frequently accompanied with 
solid brain metastases in 50% of patients and even more frequently with extracranial 
metastases. The situation is different in patients with germ cell tumors of the CNS such as 
germinomas and in patients affected by medulloblastoma. Here, leptomeningeal disease is 
frequently found already at the time of initial diagnosis, not necessarily associated with poor 
prognosis, and therapy may still be curative. 
It must be assumed that leptomeningeal tumor cell spread is rather underdiagnosed in the 
clinical setting since the available diagnostic procedures are not adequately sensitive to 
confirm the diagnosis in all cases (see below). Furthermore, diagnosis is not always forced in 
patients who have multiple systemic tumor manifestations in the absence of convincing 
treatment options.  
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Basically, there are 2 different types of leptomeningeal tumor manifestation: (i) solid tumor 
deposits and (ii) rather diffuse, non-adherent accumulation of tumor cells in the cerebrospinal 
fluid (CSF). A combination of both conditions is also found. 
The clinical symptoms associated with neoplastic meningitis are symptoms due to increased 
intracranial pressure because of hydrocephalus such as nausea and vomiting, headaches 
and neck pain as well as confusion. Cranial nerve palsies resulting in diplopia, hemifacial 
weakness and radicular symptoms and signs like pain, paresthesia, paresis as well as loss of 
bladder or bowel control can also occur. 
Neoplastic meningitis in patients with solid tumors has a poor prognosis. In the absence of 
treatment, median survival is typically in the range of 6-8 weeks. In patients with 
hematological neoplasms, the prognosis is better but still limited. Tumor-specific treatment 
such as radiotherapy or chemotherapy results in prolonged survival times which, however, 
are still restricted to a median of 2-8 months. Again, the prognosis is better for patients 
affected by lymphoma or leukemia. Furthermore, the disease course is somewhat more 
favorable in breast cancer patients which probably reflects the higher sensitivity of these 
tumor cells to irradiation and medical anti-tumor treatment. Still, it needs to be considered 
that the majority of patients affected by leptomeningeal disease do not die from tumor cell 
dissemination in the CSF but from systemic tumor progression. Negative prognostic factors 
associated with leptomeningeal tumor cell dissemination are low Karnofsky performance 
status, increased age, uncontrolled intracranial pressure as well as low glucose and high 
protein levels in the CSF 3-6. 
 
Diagnostic procedures 
 
Patients with suspected neoplastic meningitis require a thorough diagnostic assessment with 
a detailed neurological examination as the first step. Here, particular attention should be paid 
to symptoms or signs caused by increased intracranial pressure as well as cranial nerve 
alterations. Symptoms evoked by extracranial tumor manifestations should also be taken into 
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consideration. Imaging should comprise brain and spinal cord examination to allow for a 
comprehensive assessment of the subarachnoid space. Small tumor manifestations are 
typically only detected by MRI which is the gold standard (Figure 1). CT scans may just allow 
for the exclusion of significant hydrocephalus. Finally, CSF analysis is required to determine 
cell count, opening pressure as well as protein, glucose and lactate levels. CSF cytology and 
immunohistochemical analyses may further help to confirm or exclude the presence of tumor 
cells. Markers such as alpha-fetoprotein or beta-HCG may be helpful in patients with 
(suspected) germ cell tumors. Here, CSF levels should always be compared with serum 
concentrations. Genomic alterations in tumor cells from the CSF can be detected by copy 
number analysis and may indicate their malignant origin 7. This approach however, has not 
yet reached clinical routine. 
A recurrent challenge in the diagnosis of neoplastic meningitis which is suspected by clinical 
or imaging findings is negative CSF cytology despite advanced histological work-up 8. Here, 
flow cytometry which allows for an assessment of specific cell surface markers, e.g. 
epithelial-cell adhesion molecule (EpCAM) in patients with epithelial-cell cancers, may help 
to increase the diagnostic sensitivity 9-11. Monoclonal cell populations may be detectable by 
PCR, e.g. IgH rearrangements in lymphomas, and fluorescence in situ hybridization (FISH) 
can be used to detect chromosomal alterations 12. Such analyses, however, are often difficult 
to perform when only few cells are available and may be restricted to specialized 
laboratories. Another novel technique called “rare cell capture technology” (RCCT) uses anti-
EpCAM antibody-covered magnetic nanoparticles to identify tumor cells. RCCT may increase 
the diagnostic sensitivity for tumor cell dissemination in the CSF but has not yet reached 
broad utilization 13.  
 
Therapeutic approaches 
 
There are only few prospective, randomized trials for patient with neoplastic meningitis. 
Thus, most therapeutic recommendations must be considered as low-level evidence and are 
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mainly based on small clinical series, retrospective analyses or clinical experience. Because 
of the limited activity of the available therapeutic options, treatment goals must be carefully 
evaluated. Reduction of neurological symptoms and pain as well as limited life extension 
must be weighed against the side effects which are associated with any treatment. 
Accordingly, for some patients, best supportive care which aims at improving symptom 
control may be an appropriate approach. For those patients who are considered eligible for 
tumor-specific treatment, there are basically 3 therapeutic approaches which may be used as 
single treatment or in combination. There are no clear guidelines which treatments fits best 
for each patient. However, there is a consensus that the type of leptomeningeal tumor 
manifestation as assessed by MRI as well as the presence or absence of solid brain 
metastases and extracranial metastases defines the most appropriate therapeutic approach. 
Commonly, patients present with a combination of solid tumor manifestations in the 
leptomeninges and additional diffuse, non-adherent tumor cell spread. Accordingly, a 
combination of different therapeutic modalities is frequently required (Table 1).  
 
Radiation therapy 
 
Craniospinal irradation is only rarely performed because of significant bone marrow toxicity 
that can be associated with this approach. Irradiation of the entire neuroaxis is typically 
restricted to patients with leptomeningeal dissemination of primary brain tumors. Patients 
who are treated in such a way are rarely treated concomitantly with systemic chemotherapy 
and never with intrathecal therapy because of the increased risk of side effects. In most 
patients with neoplastic meningitis, whole brain radiation therapy (WBRT) which includes the 
subarachnoid space is used as a more focal approach 14. Typically, the chosen irradiation 
field involves the skull base as well as interpeduncular cisterns and the first cervical 
vertebrae (C1 and C2). WBRT is mostly administered in 3 Gy fractions to a total dose of 30-
36 Gy. Focal spinal tumor manifestations are irradiated using a safety margin of one 
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vertebral body above and below the lesion. Here, various fractionations are used, e.g. 5 x 2-3 
Gy/week with a total dose of 30–36 Gy.  
There are no controlled clinical trials assessing the activity of irradiation in patients with 
neoplastic meningitis. A retrospective series of patients with leptomeningal carcinomatosis 
from non-small cell lung cancer (NSCLC) did not suggest a survival prolongation by WBRT 
15. Still, radiation may help to restore CSF flow and reduce clinical symptoms. Therefore, it 
remains a treatment option for patients with leptomeningeal disease in the absence of other 
convincing therapeutic strategies. 
 
Systemic chemotherapy and targeted therapy 
 
Solid tumor manifestations in the brain probably respond to systemic therapy in a similar way 
as other systemic metastases 16,17. Accordingly, it can be assumed that solid leptomeningeal 
tumor lesions can be treated with systemic therapy. However, larger trials assessing this 
approach are largely lacking and the available evidence originates from a limited number of 
series 18,19. Whether the introduction of novel drugs within the last years such as pemetrexed, 
bevacizumab or tyrosine kinase inhibitors in patients with NSCLC improves the outcome of 
neoplastic meningitis remains unclear 20. Similar to parenchymal brain metastases, the best 
treatment for the primary tumor is also the best choice for the treatment of leptomeningeal 
disease. Many patients have already received one or more lines of systemic chemotherapy 
and therefore, when leptomenigeal caricinomatosis is diagnosed, only limited treatment 
options remain available. Another unresolved point remains the combination of systemic and 
intrathecal treatment. In breast cancer patients, the addition of intrathecal treatment to 
systemic chemotherapy did not result in improved outcome 21,22. Patients who suffer from 
non-adherent tumor cell dissemination in the CSF may benefit from systemic treatment 
provided that the chosen drug crosses the blood-CSF barrier at sufficient concentrations. 
Accordingly, promising results have been reported in patients who were treated with high-
dose methotrexate (MTX) 19.  
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Targeted therapies using small molecule inhibitors have gained increasing interest during the 
last years. It has been reported that higher CSF levels of the EGFR inhibitor erlotinib may be 
achieved with an alternating dosing regimen compared to the standard schedule 23. 
Retrospective analyses suggest that erlotinib may improve the outcome of NSCLC patients 
with leptomeningeal carcinomatosis 24. Erlotinib may therefore be a valuable treatment option 
for patients with leptomeningeal carcinomatosis with tumors cell that harbor a sensitizing 
EGFR mutation. Compared to gefitinib, another EGFR inhibitor, erlotinib may achieve higher 
CSF concentrations and result in better control rates of leptomeningeal dissemination 25. 
 
Intrathecal treatment 
 
Intrathecal administration of drugs aims at efficiently targeting tumor cells in the CSF by 
circumventing the blood-CSF barrier while omitting systemic toxicity. However, drugs which 
are administered intrathecally probably have a limited penetration into solid leptomeningeal 
tumor deposits. Therefore, this approach is mainly restricted to patients who have non-
adherent tumor cell spread in the CSF. Basically, treatment can be done following a lumbar 
puncture and subsequent drug injection. However, this approach has several drawbacks: 
repeated lumbar punctures are inconvenient for the patient and associated with an increased 
risk for misinjection and post puncture headache as well as complications such as infections 
or bleeding related to the procedure. Furthermore, distribution of the drug in the intra- and 
extraventricular CSF compartments may be insufficient 26. Therefore, it is recommended to 
place an intraventricular catheter system such as an Ommaya or Rickham reservoir. These 
devices allow for repeated injections and a better distribution of the drug. Among the drugs 
which are available for intrathecal treatment, MTX and cytarabine are most frequently used. 
Alternatively, thiotriethylenephosphoramide (thiotepa) has been approved in some countries. 
However, a retrospective analysis on the use of thiotepa in breast cancer patients with 
leptomeningeal carcinomatosis suggested only limited activity 27.  MTX is typically given twice 
per week using single doses of 12-15 mg. No adaption to body weight or body surface area 
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is required. In order to avoid system toxicity of MTX, folinic acid rescue should be started 6 
hours after the first injection and continued in 6 h intervals for 48 h. Cytarabine is also 
administered twice weekly using 40 mg per injection. MTX can be considered the standard of 
care for patients with neoplastic meningitis originating from solid tumors whereas cytarabine 
is more frequently used in patients affected by lymphoma or leukemia. In a randomized trial, 
neither MTX nor thiotepa displayed a superior activity 28. 
Liposomal cytarabine (DepoCyte®) is a sustained-release form of cytarabine. Liposomal 
cytarabine was compared with MTX in a controlled trial in patients with solid tumors and 
leptomeningeal carcinomatosis. Patients who were treated with liposomal cytarabine 
experienced a longer time until neurological progression. However, there was no significant 
difference in overall survival 29. In patients with leptomeningeal lymphomatosis, liposomal 
cytarabine resulted in higher response rates and improved quality of life compared to 
standard cytarabine 30 and is therefore a treatment option which may be considered for these 
patients. In a large retrospective analysis of breast cancer patients with leptomeningeal 
metastasis, liposomal cytarabine was similarly effective as MTX 31. Liposomal cytarabine 
requires only administration in 2 week intervals and may achieve more equal CSF 
distribution than non-liposomal cytarabine 32,33. In contrast, liposomal cytarabine is 
associated with an increased risk for radiculitis and arachnoiditis. The occurrence of 
arachnoiditis might be prevented by a prophylactic oral administration of dexamethasone (12 
mg/day) starting with the first day of intrathecal treatment. A combination of radiation therapy 
and concomitant liposomal cytarabine administration has not been examined in controlled 
trials. Accordingly, there is a remaining concern that such a combination may results in 
neurotoxicity. Caution needs also to be taken in patients who are being treated with systemic 
chemotherapy that crosses the blood-brain barrier such as high-dose MTX or cytarabine. 
The addition of intrathecal treatment with liposomal cytarabine can result in significant 
neurotoxicity 34,35.  
Data from a recent phase II study suggest that ventriculolumbar perfusionchemotherapy with 
MTX which represents continuous intraventricular perfusion through an intraventricular 
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reservoir and drainage via lumbar catheter may allow for a better control of intracranial 
pressure and improved symptom control 36. These results, however, require confirmation in a 
larger trial. 
There are no data available that support a combination of several drugs for intrathecal 
therapy. In contrast, data from rather old studies suggest no beneficial effect 37-39. Drugs 
which have already been used for intrathecal treatment include mafosfamide 40, topotecan 41 
and etoposide 42. However, their administration must be considered as compassionate use. 
Emerging evidence exists for the use of intrathecal trastuzumab in patients with HER2/neu-
positive breast cancer 43,44. Trastuzumab may be an active treatment which is overall well 
tolerated. The CD20 antibody rituximab has been administered intrathecally in patients with 
leptomeningeal lymphomatosis and was well tolerated. However, it remains to be determined 
whether this treatment approach results in a survival benefit 45.   
At the beginning of treatment, WBC should be > 3.000/µl and platelets > 100.000/µl. Patients 
who are treated with MTX should have sufficient renal function. Otherwise, a close evaluation 
of potential toxicity is required. Intrathecal therapy should be performed without mixing drug 
solutions with other agents such as steroids. Overall, there are no clear guidelines on 
whether and how irradiation and intrathecal treatment should be combined. Because of the 
risk of side effects, a combined administration of both treatment modalities should only be 
done after a careful evaluation. Intrathecal treatment is mostly interrupted until irradiation has 
been completed or should be reduced to a one weekly administration. In most centers, 
irradiation is put on hold at the day of intrathecal treatment.  
The duration of intrathecal therapy has not been standardized either. Clinical symptoms as 
well as CSF and MRI findings should be taken into account to decide whether the therapy 
should be continued or interrupted. Treatment aims at clearing the CSF from tumor cells 
within 2 weeks but may be continued on an individual basis. Early neurological and 
cytological responses may predict longer time-to-progression and overall survival 46. MRI 
responses are frequently difficult to determine and are of only limited help due to a lack of 
standardization with respect to response criteria 47. Clinical deterioration or continuous 
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worsening of the CSF findings during therapy, e.g. an increasing number of tumor cells, 
requires an adaption of the treatment. Changing the therapeutic regimen to another drug or 
switching from chemotherapy to irradiation are the available options. Conversely, intrathecal 
therapy can be stopped when 2 subsequent CSF samples are free from tumor cells. No data 
are available which support the administration of a consolidation or maintenance therapy. In 
the case of tumor recurrence following prior clearance of the CSF, the same drug should be 
used as first choice.  
 
Supportive therapy 
 
Patients affected by neoplastic meningitis may suffer from various clinical symptoms as 
described above. Symptom relief is therefore a major goal of any chosen therapy. Here, 
steroids may help to decrease symptom burden similar to the situation of solid tumor 
manifestations in the brain 48. There are no particular treatment considerations for patients 
with leptomeningeal carcinomatosis available and dexamethasone in a dose of 4-16 mg/day 
may be considered a reasonable starting dose. Tapering should be considered whenever 
possible because of the manifold side effects associated with prolonged steroid use.  
Patient who suffer from symptoms related to increased intracranial pressure because of 
hydrocephalus frequently benefit from ventriculoperitoneal shunting. Despite the risk of tumor 
cell dissemination from the CSF into the peritoneal cavity, this seems to occur only rarely 49. 
Seizures should be treated with an appropriate anticonvulsant. Drugs which do not interact 
with other compounds such as chemotherapeutic agents are preferred 50.  
 
Outlook 
 
Neoplastic meningitis remains a therapeutic challenge. The small number of controlled trials 
limits the available evidence for the different therapeutic options resulting in various non-
standardized treatment regimens. Furthermore, there is a lack of data for specific tumor 
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entities and clinical trials focusing on selected histological tumor types would be most helpful. 
The activity of many drugs which have become available within the last years remains largely 
unknown. A rigorous assessment of these drugs within clinical trials may help to define a 
better therapeutic management of patients affected by leptomeningeal tumor dissemination. 
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Legend to Figure 1 
A. T1 contrast-enhanced MRI of a melanoma patient with leptomeningeal tumor 
dissemination with most pronounced alternations in the central sulcus. B. Leptomeningeal 
tumor manifestations in a patient affected by anaplastic astrocytoma (T1 contrast-enhanced 
MRI). 
 
 
